source
- Regeneron posts mid-stage POTS data; Kyverna completes CAR-T filingPlus, news about Merck KGaA, Rezolute, Vir, Orakl and Cellectis. Regeneron’s mid-stage POTS data: The biotech’s monoclonal antibody, baloncibart, given at 450 mg led to an average 11.4-beat-per-min…
- Marrow extracts $120M series B to advance preclinical blood disease therapyA new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta th…